Matches in SemOpenAlex for { <https://semopenalex.org/work/W4250268587> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W4250268587 endingPage "760" @default.
- W4250268587 startingPage "760" @default.
- W4250268587 abstract "760 Background: Most chemotherapy regimens have marginal activity in pts with heavily pretreated MBC, with the exception of X, which consistently results in overall response rates (ORR) of approximately 20% and overall survival of around 1 year. We studied the efficacy and safety of X in heavily pretreated pts with MBC, with a view to identifying potential predictors of progression-free survival (PFS). Methods: Pts received X 1000 mg/m2 twice daily for 14 days every 3 weeks. We analyzed ER/PR and cerbB-2 expression by immunohistochemistry (IHC). Results: 56/58 pts had prior anthracyclines and taxanes either as adjuvant or MBC therapy, 3% had cardiac contraindication to anthracyclines, 72% had ≥3 prior regimens, 50% had >1 metastatic site, 45% were ER/PR positive, and 60% were cerbB-2 positive (includes +1, +2, +3). Grade 3/4 adverse events were seen in 17 pts (29%): HFS (7%), fatigue (5%), loss of appetite (3%), dyspepsia (3%), nausea (2%), conjunctivitis (2%), infection (2%), elevated bilirubin (3%), elevated ALT (2%). The ORR was 17% with a median duration of 9.4 months. Median PFS was 5 months (95% CI 3.53–6.47 months). Neither the number of metastatic sites nor hormone receptor status was correlated to PFS, although there was a difference between cerbB-2 negative and cerbB-2 positive pts (p<0.05). When only cerbB-2 ≥2+ pts were considered, the difference was non-significant. In the 31 pts who were cerbB-2 ≥2+, the ORR was 10%, and 45% had SD; in the 22 pts with cerbB-2 0 or 1+, the ORR and SD rates were 32% and 55%, respectively. PFS in cerbB-2 ≥2+ vs. 0 or 1+ was 3.7 months vs. 7.4 months (p=0.012). Conclusions: These results compare favorably with the large available database on X, confirming that X has substantial antitumor activity and favorable safety in this setting. Enhanced antitumor activity was observed in patients with cerbB-2 negative MBC compared to positive. As cerbB-2 expression is a known negative prognostic factor in MBC, the combination of X and trastuzumab would likely improve outcomes in cerbB-2 ≥2+ pts. No significant financial relationships to disclose." @default.
- W4250268587 created "2022-05-12" @default.
- W4250268587 creator A5034022202 @default.
- W4250268587 creator A5037739101 @default.
- W4250268587 creator A5047393907 @default.
- W4250268587 creator A5053173121 @default.
- W4250268587 creator A5058883099 @default.
- W4250268587 creator A5065482599 @default.
- W4250268587 creator A5073903471 @default.
- W4250268587 date "2004-07-15" @default.
- W4250268587 modified "2023-09-28" @default.
- W4250268587 title "Capecitabine (X) monotherapy in patients (pts) with pretreated metastatic breast cancer (MBC): Is response correlated to cerbB-2 expression?" @default.
- W4250268587 doi "https://doi.org/10.1200/jco.2004.22.14_suppl.760" @default.
- W4250268587 hasPublicationYear "2004" @default.
- W4250268587 type Work @default.
- W4250268587 citedByCount "0" @default.
- W4250268587 crossrefType "journal-article" @default.
- W4250268587 hasAuthorship W4250268587A5034022202 @default.
- W4250268587 hasAuthorship W4250268587A5037739101 @default.
- W4250268587 hasAuthorship W4250268587A5047393907 @default.
- W4250268587 hasAuthorship W4250268587A5053173121 @default.
- W4250268587 hasAuthorship W4250268587A5058883099 @default.
- W4250268587 hasAuthorship W4250268587A5065482599 @default.
- W4250268587 hasAuthorship W4250268587A5073903471 @default.
- W4250268587 hasConcept C121608353 @default.
- W4250268587 hasConcept C126322002 @default.
- W4250268587 hasConcept C142724271 @default.
- W4250268587 hasConcept C143998085 @default.
- W4250268587 hasConcept C197934379 @default.
- W4250268587 hasConcept C204787440 @default.
- W4250268587 hasConcept C2775930923 @default.
- W4250268587 hasConcept C2776494729 @default.
- W4250268587 hasConcept C2776694085 @default.
- W4250268587 hasConcept C2777909004 @default.
- W4250268587 hasConcept C2780580376 @default.
- W4250268587 hasConcept C2780739268 @default.
- W4250268587 hasConcept C526805850 @default.
- W4250268587 hasConcept C530470458 @default.
- W4250268587 hasConcept C71924100 @default.
- W4250268587 hasConcept C90924648 @default.
- W4250268587 hasConceptScore W4250268587C121608353 @default.
- W4250268587 hasConceptScore W4250268587C126322002 @default.
- W4250268587 hasConceptScore W4250268587C142724271 @default.
- W4250268587 hasConceptScore W4250268587C143998085 @default.
- W4250268587 hasConceptScore W4250268587C197934379 @default.
- W4250268587 hasConceptScore W4250268587C204787440 @default.
- W4250268587 hasConceptScore W4250268587C2775930923 @default.
- W4250268587 hasConceptScore W4250268587C2776494729 @default.
- W4250268587 hasConceptScore W4250268587C2776694085 @default.
- W4250268587 hasConceptScore W4250268587C2777909004 @default.
- W4250268587 hasConceptScore W4250268587C2780580376 @default.
- W4250268587 hasConceptScore W4250268587C2780739268 @default.
- W4250268587 hasConceptScore W4250268587C526805850 @default.
- W4250268587 hasConceptScore W4250268587C530470458 @default.
- W4250268587 hasConceptScore W4250268587C71924100 @default.
- W4250268587 hasConceptScore W4250268587C90924648 @default.
- W4250268587 hasIssue "14_suppl" @default.
- W4250268587 hasLocation W42502685871 @default.
- W4250268587 hasOpenAccess W4250268587 @default.
- W4250268587 hasPrimaryLocation W42502685871 @default.
- W4250268587 hasRelatedWork W191016762 @default.
- W4250268587 hasRelatedWork W1989412474 @default.
- W4250268587 hasRelatedWork W2092771806 @default.
- W4250268587 hasRelatedWork W2139647583 @default.
- W4250268587 hasRelatedWork W2139955290 @default.
- W4250268587 hasRelatedWork W2275049615 @default.
- W4250268587 hasRelatedWork W2589453077 @default.
- W4250268587 hasRelatedWork W2606937945 @default.
- W4250268587 hasRelatedWork W2782589310 @default.
- W4250268587 hasRelatedWork W3212173559 @default.
- W4250268587 hasVolume "22" @default.
- W4250268587 isParatext "false" @default.
- W4250268587 isRetracted "false" @default.
- W4250268587 workType "article" @default.